|Biotech partner:||Intercell (Austria) Cytos Biotechnology (Switzerland)|
|Type of agreement:||* other
|Compound:||platform technology for monoclonal antibody discovery|
|Disease area:||infectious diseases with a focus on group B Streptococcus and bacteria involved in hospital acquired infections|
|Nature of the agreement:||Intercell AG has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos's platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases. Intercell will own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates discovered by Cytos.
The key scientists, who have very successfully developed the technology at Cytos, will be employed by Intercell.
- On June 8, 2010, Intercell announced the closing of the acquisition of Cytos'platform technology for monoclonal antibody discovery.
|Financial terms of the agreement:||Under the agreed terms Intercell will pay €15 million to Cytos.|